A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...

Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing ...

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with ...

Two different doses of sebetralstat significantly reduced anxiety compared with placebo during hereditary angioedema (HAE) attacks.

The biotechnology giant has not ruled out expanding its pipeline of treatments through acquisitions after a number of ...

Navenibart is an investigational monoclonal antibody that blocks plasma kallikrein. The Food and Drug Administration (FDA) has granted Orphan Drug designation to navenibart for the treatment of ...

JonesTrading analyst Debanjana Chatterjee has assigned their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that five abstracts have been accepted for e-Poster ...

Astria Therapeutics won Food and Drug Administration orphan-drug designation for navenibart, its lead program candidate, for the treatment of the rare genetic disease hereditary angioedema.

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...